» Articles » PMID: 23149893

Imaging Hypoxia to Improve Radiotherapy Outcome

Overview
Specialty Oncology
Date 2012 Nov 15
PMID 23149893
Citations 235
Authors
Affiliations
Soon will be listed here.
Abstract

Reduced oxygen levels (hypoxia) is one of the most important factors influencing clinical outcome after radiotherapy. This is primarily because hypoxic cells are resistant to radiation treatment; hence, the greater the number of clonogenic cancer stem cells that exist under hypoxia, the lower the local tumour control. Reduced local control will influence overall survival, as may the hypoxic conditions by increasing malignant progression; however, to fight hypoxia, we should first be able to see it. We need noninvasive approaches that can accurately and reliably image hypoxia in tumours, especially using techniques that are routinely available in the clinic, such as PET, MRI and CT. All these imaging methods are already under clinical evaluation in this context. Such data should allow us to identify those patients on an individual basis who have hypoxic tumours and, thus, at the very least should receive some form of hypoxic modifier in conjunction with radiotherapy. Alternatively, the radiation dose could be either increased to the whole tumour or, if the imaging is accurate enough, only to the hypoxic subvolumes. The aim of this Review is to critically assess the potential use of imaging to help improve clinical outcome to radiotherapy.

Citing Articles

Oxygen saturation imaging elucidates tumor heterogeneity in gastric cancer.

Minamide T, Minakata N, Yamashita R, Sakashita S, Yoda Y, Ohashi A DEN Open. 2025; 5(1):e70077.

PMID: 39991264 PMC: 11843471. DOI: 10.1002/deo2.70077.


Identification of robust RT-qPCR reference genes for studying changes in gene expression in response to hypoxia in breast cancer cell lines.

Malcolm J, Bridge K, Holding A, Brackenbury W BMC Genomics. 2025; 26(1):59.

PMID: 39838295 PMC: 11748566. DOI: 10.1186/s12864-025-11216-6.


Anti-Inflammatory and Anticancer Effects of Kaurenoic Acid in Overcoming Radioresistance in Breast Cancer Radiotherapy.

Kim T, Ko S Nutrients. 2025; 16(24.

PMID: 39770941 PMC: 11677055. DOI: 10.3390/nu16244320.


Nitric Oxide-Releasing Nanoscale Metal-Organic Layer Overcomes Hypoxia and Reactive Oxygen Species Diffusion Barriers to Enhance Cancer Radiotherapy.

Xiong Y, Li J, Jiang X, Zhen W, Ma X, Lin W Adv Sci (Weinh). 2025; 12(8):e2413518.

PMID: 39742392 PMC: 11848595. DOI: 10.1002/advs.202413518.


Role of exosomes in modulating non-small cell lung cancer radiosensitivity.

Fang J, Rao X, Wang C, Wang Y, Wu C, Zhou R Front Pharmacol. 2024; 15:1471476.

PMID: 39737074 PMC: 11683128. DOI: 10.3389/fphar.2024.1471476.


References
1.
Helmlinger G, Yuan F, Dellian M, Jain R . Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med. 1997; 3(2):177-82. DOI: 10.1038/nm0297-177. View

2.
Denekamp J, Dasu A . Inducible repair and the two forms of tumour hypoxia--time for a paradigm shift. Acta Oncol. 1999; 38(7):903-18. DOI: 10.1080/028418699432590. View

3.
Yuan H, Schroeder T, Bowsher J, Hedlund L, Wong T, Dewhirst M . Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2006; 47(6):989-98. View

4.
Vaupel P, Kallinowski F, Okunieff P . Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989; 49(23):6449-65. View

5.
Piert M, Machulla H, Picchio M, Reischl G, Ziegler S, Kumar P . Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med. 2005; 46(1):106-13. View